We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biopharm Startup to Commercialize Antibody Therapy for Drug Resistant Cancers

By LabMedica International staff writers
Posted on 05 Jul 2015
Print article
A biopharm startup company has licensed the rights to commercialize an antibody-based approach for treatment of drug resistant cancers.

The new company, CadheRx Therapeutics (La Jolla, CA, USA), entered into a licensing agreement with Stony Brook University (NY, USA) to develop and market an anticancer technology derived from research performed in the laboratory of Dr. Sabine Brouxhon, associate professor of emergency medicine at Stony Brook University.

Dr. Brouxhon's approach is based on antibodies that target soluble E-cadherin. Soluble E-cadherin levels have been shown to be elevated in the microenvirnoment of many solid tumors and contribute to enhanced tumor cell proliferation, migration, and invasion, which is linked to metastatic disease.

“One of the most significant drawbacks from current cancer treatments is that despite their initial effectiveness against solid tumors, patients often develop resistance to these treatments,” said Dr. Brouxhon. “Our lab has discovered a novel antibody-based cancer therapy that acts through a completely different mechanism of action compared to existing drugs in industry. Notably, the antibody down-regulates multiple resistant pathways, thereby minimizing the cancer cells ability to recruit many interconnected oncogenes that are linked with resistant disease.”

Under terms of the licensing agreement CadheRx Therapeutics will create targeted antibody agents to counter de novo or acquired resistance. The company is financially backed by Avalon Ventures (La Jolla, CA, USA) and is one of six startup companies formed from collaboration between Avalon Ventures and GlaxoSmithKline (London, United Kingdom) that began in April 2013.

“It is extraordinarily exciting to see a basic research discovery from a Stony Brook University scientist turn into something that might improve people’s lives in a very powerful way,” said Dr. Samuel L. Stanley Jr., president of Stony Brook University. “Cancer affects millions of people worldwide, and Dr. Brouxhon’s work on this new anticancer technology offers continued hope in the fight against many forms of cancer.”

Related Links:

Stony Brook University
Avalon Ventures
GlaxoSmithKline


New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
PSA Test
Human Semen Rapid Test
New
FLU/RSV Test
Humasis FLU/RSV Combo

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.